65,437 trials
Colorectal Cancer Screening
Primary: Time to Cecal Intubation. — 310; 306 Seconds
Intracranial Pressure Increase · Abdominal Compartment Syndrome
Primary: Changes in Vasopressin Levels During Pneumoperitoneum and Elevated PEEP — 2.37; 45.48; 54.75; 31.57 pg/ml — p=<0.0001
Anal Intraepithelial Neoplasia · High Grade Squamous Intraepithelial Neoplasia · HIV Positivity
Primary: Overall Response Rate at 48 Weeks — 10 Participants
Depression Mild · Depressive Disorder, Major · Mild Cognitive Impairment
Primary: Trail Making Part B Test — 5.06; -1.55 seconds
Tonsillar Hypertrophy
Primary: Change of Tonsil(s) Size at 3 Months Compared to the Baseline. — -1.13; -1.26 Scores on a scale
Attention Deficit Hyperactivity Disorder
Primary: Passive Audio Data-Positive Sentiment Analysis — 0.409; 0.369; 0.388 Proportion Positive Sentiment
Rhinitis, Allergic, Seasonal
Primary: CSMS (Combined Symptom and Medication Score) Averaged Over the Peak Grass Pollen Season (GPS) — 1.14; 1.03; 1.70; 1.42 score on a scale — p=0.0325
Caregivers of People With Dementia
Primary: Mean Change in PHQ-9 to Assess Depressive Symptoms — 1.6 score on a scale
Acute Spinal Cord Injury
Primary: Feasibility of Intraoperative Contrast-enhanced Ultrasound in Acute Traumatic Spinal Cord Injury - Number of Participants With Successful Intraoperative…
Gastroparesis · Dyspepsia
Primary: Frequency of Contractions at Baseline — 20; 24.6; 23.7 stomach contractions/minute
Injury Leg
Primary: Region of Limb Stability — 68.16 cm2
Social Anxiety Disorder of Childhood
Primary: P1 Amplitude Elicited in the Dot-probe Task — 7.04; 5.61 microvolts
Evidence Based Programs in Schools
Primary: Best in Class (BiC) Adherence: Sustainment Average (SU1-SU4) vs. Implementation Post-Baseline Average (IM2-IM4) (Teacher Level Sample) — -.075 score on BiC
Sickle Cell Disease
Primary: Percentage of Participants With Two-Year Post-Transplant Event Free Survival (EFS) — 88.0; 79.3 Percentage of Participants
Chronic Hepatitis b
Primary: The Frequency and Severity of Treatment Emergent Adverse Events (TEAEs), Discontinuations Due to AEs and Lab Abnormalities After Dosing With AB-729 Plus Peg-IFNα-2a…